Nasdaq

Precision BioSciences to present preclinical PBGENE-HBV data

Precision BioSciences (DTIL) will present preclinical data supporting the advancement of PBGENE-HBV into clinical development. The company will also outline the design of its first-in-human study, ...
JSTOR Daily

N6-methyladenosine modification of the 5′ epsilon structure of the HBV pregenome RNA regulates its encapsidation by the viral core protein

Hepatitis B virus (HBV) contains a partially double-stranded DNA genome. During infection, its replication is mediated by reverse transcription (RT) of an RNA intermediate termed pregenomic RNA (pgRNA ...
JSTOR Daily

The Loss-of-Function S267F Variant in HBV Receptor NTCP Reduces Human Risk for HBV Infection and Disease Progression

Background. Sodium taurocholate cotransporting polypeptide (NTCP, SLC10A1) is a hepatocyte receptor for hepatitis B virus (HBV) infection. The natural NTCP S267F variant causes loss of NTCP HBV ...
News Medical

Novel immune cell therapy may be a promising strategy for combating HBV infection

Chronic infection with the hepatitis B virus (HBV) causes progressive liver problems, and eradication of the virus remains a formidable challenge. New research in FEBS Letters indicates that treatment ...
BioWorld

Lion TCR raises $40M in series B to advance cell therapy for HBV-related liver cancer

Lion TCR Pte. Ltd. raised $40 million in series B funding that will see the company advance its clinical trial program for its hepatitis B virus (HBV)-specific T-cell receptor (TCR) cell therapy for ...